Search results

710 results

Sorted by Date . Sort by Relevance

In development Remove In development filter
Proposed Remove Proposed filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Interventional procedures guidance Remove Interventional procedures guidance filter
Antimicrobial prescribing guidelines Remove Antimicrobial prescribing guidelines filter
Safe staffing guidelines Remove Safe staffing guidelines filter
Social care guidelines Remove Social care guidelines filter
Medicines practice guidelines Remove Medicines practice guidelines filter

Berotralstat for preventing acute attacks of hereditary angioedema [ID1624]

In development [GID-TA10650] Expected publication date: 25 August 2021

Type

Technology appraisal guidance

Status

In development
Risdiplam for treating spinal muscular atrophy in children and adults [ID1631]

In development [GID-TA10612] Expected publication date: 21 July 2021

Type

Technology appraisal guidance

Status

In development
Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 alterations [ID3740]

In development [GID-TA10619] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy [ID3735]

In development [GID-TA10624] Expected publication date: 23 June 2021

Type

Technology appraisal guidance

Status

In development
Glasdegib with chemotherapy for untreated acute myeloid leukaemia [ID1334]

In development [GID-TA10314] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer ID1357

In development [GID-TA10322] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]

In development [GID-TA10555] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]

Proposed [GID-TA10764] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Semaglutide for managing overweight and obesity [ID3850]

Proposed [GID-TA10765] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Transvenous obliteration of varices

In development [GID-IPG10206] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Image-guided cryoablation of peripheral neuroma for chronic pain

In development [GID-IPG10208] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Laparoscopic insertion of a magnetic titanium ring for gastro-oesophageal reflux disease

In development [GID-IPG10209] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma ID1305

In development [GID-TA10244] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Spasticity (after stroke) - botulinum toxin type A [ID768]

In development [GID-TAG499] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Anamorelin for treating anorexia and cachexia associated with non-small cell lung cancer [ID821]

In development [GID-TA10105] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]

In development [GID-TA10089] Expected publication date: 15 November 2017

Type

Technology appraisal guidance

Status

In development
Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)

In development [GID-TA10527] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Secondary infection of common skin conditions including eczema: antimicrobial prescribing

In development [GID-NG10135] Expected publication date: 02 March 2021

Type

Antimicrobial prescribing guideline

Status

In development
Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]

In development [GID-TA10458] Expected publication date: 19 May 2021

Type

Technology appraisal guidance

Status

In development
Eculizumab for treating relapsing neuromyelitis optica [ID1271]

In development [GID-TA10469] Expected publication date: 02 September 2020

Type

Technology appraisal guidance

Status

In development
Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340

In development [GID-TA10313] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Dupilumab for treating chronic rhinosinusitis with nasal polyps ID1179

In development [GID-TA10450] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab for treating resected high-risk invasive urothelial cancer [ID2694]

In development [GID-TA10742] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Solriamfetol for treating excessive waketime sleepiness caused by narcolepsy [ID1602]

In development [GID-TA10524] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea [ID1499]

In development [GID-TA10430] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea ID1065

In development [GID-TA10385] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab with platinum-based chemotherapy for advanced unresectable, recurrent or metastatic previously untreated oesophageal cancer [ID2712]

In development [GID-TA10572] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]

Proposed [GID-TA10598] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Olaparib for treating BRCA 1 or 2 mutated metastatic breast cancer after prior chemotherapy [ID1382]

In development [GID-TA10342] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation [ID1582]

In development [GID-TA10495] Expected publication date: 18 August 2021

Type

Technology appraisal guidance

Status

In development
Tebentafusp for treating metastatic HLA-A*02:01 positive uveal melanoma (ID1441)

In development [GID-TA10428] Expected publication date: 04 May 2022

Type

Technology appraisal guidance

Status

In development
Imlifidase for preventing kidney transplant rejection in people with chronic kidney disease [ID1672]

Proposed [GID-TA10552] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Atezolizumab monotherapy for untreated PD-L1 positive metastatic non-small-cell lung cancer [ID1678]

In development [GID-TA10587] Expected publication date: 02 June 2021

Type

Technology appraisal guidance

Status

In development
Pembrolizumab with etoposide and a platinum-based compound for untreated extensive-stage small-cell lung cancer ID1509

In development [GID-TA10413] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors [ID3813]

Proposed [GID-TA10691] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]

Proposed [GID-TA10694] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Retifanlimab for treating advanced anal canal squamous cell carcinoma after platinum-based chemotherapy [ID3815]

Proposed [GID-TA10698] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Etranacogene dezaparvovec for treating haemophilia B [ID3812]

Proposed [GID-TA10699] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tralokinumab for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3823]

Proposed [GID-TA10702] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Eptinezumab for preventing migraine [ID3803]

Proposed [GID-TA10677] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Gefapixant for treating refractory chronic cough [ID3789]

Proposed [GID-TA10678] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Remimazolam for general anaesthesia [ID3796]

Proposed [GID-TA10679] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency [ID3791]

Proposed [GID-TA10680] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]

Proposed [GID-TA10682] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]

Proposed [GID-TA10684] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]

Proposed [GID-TA10683] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Transanal total mesorectal excision for rectal cancer

In development [GID-IPG10173] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Insertion and use of implantable pulmonary artery pressure monitors in chronic heart failure

In development [GID-IPG10174] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine

In development [GID-IPG10175] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]

Proposed [GID-TA10723] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed